- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.11.25 | CMS to launch model to lower Medicaid drug spending | ||
| 07.11.25 | Patient dies in Intellia trial; FDA awards 6 more 'national priority' vouchers | ||
| 07.11.25 | Pharma's clinical trial diversity push faces a new threat | ||
| 06.11.25 | Novo, Lilly cut deal with Trump to lower prices of obesity drugs | ||
| 06.11.25 | AstraZeneca exercises option to buy an obesity startup | ||
| 06.11.25 | Moderna leans on cost cuts, pipeline as vaccine sales dip | ||
| 06.11.25 | J&J brain drug acquired in $14.6B buyout cleared for broader use | ||
| 06.11.25 | Evommune nabs $150M in IPO amid federal shutdown | ||
| 05.11.25 | Knocked back by the FDA, Biohaven turns to major cost cuts | ||
| 05.11.25 | Soleno slumps despite sales uptick; Madrigal's MASH drug continues ascent | ||
| 05.11.25 | Novo narrows sales outlook as GLP-1 price cuts loom | ||
| 05.11.25 | Braveheart secures $185M to advance challenger to Bristol Myers heart drug | ||
| 04.11.25 | Blackstone pays Merck $700M to buy into ADC drug royalties | ||
| 04.11.25 | Metsera again chooses Novo as bidding war with Pfizer intensifies | ||
| 04.11.25 | Vertex's new pain, blood disorder drugs miss Wall Street expectations | ||
| 04.11.25 | Sarepta Duchenne drugs come up short in confirmatory test | ||
| 04.11.25 | Neok Bio launches with $75M to make dual-targeting ADCs | ||
| 03.11.25 | UniQure dives after FDA's 'very surprising' reversal on Huntington's gene therapy | ||
| 03.11.25 | Caribou results suggest renewed promise for 'off-the-shelf' cancer cell therapy | ||
| 03.11.25 | Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark | ||
| 03.11.25 | Roche taps an AI specialist to craft new brain drugs | ||
| 03.11.25 | 4 must-have capabilities in a digital health partner in the era of AI | ||
| 31.10.25 | Lilly quietly cuts a pain drug from its pipeline | ||
| 31.10.25 | HRSA approves 340B rebate models to hospitals' chagrin | ||
| 31.10.25 | Corporate venture firms stepped in for drug startups during biotech funding pullback |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .